TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23275042

Group type: EXPERIMENTAL
Intervention: High-dose octreotide (50 μg/h × 3d + 25 μg/h × 4d)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Low-dose octreotide (25 μg/h × 7d)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: High-dose octreotide
Number of subjects: 372
Study: 20132622

Group type: EXPERIMENTAL
Intervention: On-site in-service clinical skills training for nurse practitioners (intervention clinics)
Number of subjects: 6510

Group type: EXPERIMENTAL
Intervention: Both interventions received by clinics (intervention clinics)
Number of subjects: 6510

Group type: COMPARATOR
Intervention: Control clinics (no intervention)
Number of subjects: 6510
Study: 18606428

Group type: EXPERIMENTAL
Intervention: Non-Directly Observed Treatment (NDOT)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Directly Observed Treatment (DOT)
Number of subjects: 320
Study: 16847383

Group type: EXPERIMENTAL
Intervention: PEFG (cisplatin, epirubicin, 5‐fluorouracil, gemcitabine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 0
Study: 14650364

Group type: EXPERIMENTAL
Intervention: Pranlukast 450 mg/day for 1 to 2 years
Number of subjects: 81
Study: 11075740

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 123

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 123

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Stent implantation and CABG
Number of subjects: 123
Study: 9014622

Group type: EXPERIMENTAL
Intervention: Propofol at blood concentrations of 1‐10 micrograms ml‐1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Propofol at a dose rate of 6.3‐7.8 mg kg‐1 h‐1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Propofol at a blood concentration of 2.9 micrograms ml‐1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Concentration and dose of propofol
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Latency of the Na wave
Number of subjects: 41
Study: 1563214

Group type: EXPERIMENTAL
Intervention: 40 mg t.i.d. racemic (R,S)-propranolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: 20 mg t.i.d. optically pure (S)-propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: (R,S)-propranolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: (S)-propranolol
Number of subjects: 10
Study: 3916061

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 100
Study: 31251706

Group type: EXPERIMENTAL
Intervention: Online hypnosis intervention (hypnosis mp3s)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 43
Study: 29357902

Group type: EXPERIMENTAL
Intervention: IMRT with 30Gy in ten fractions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IMRT with 30Gy in ten fractions and SIB to 40Gy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IMRT with 20Gy in five fractions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IMRT with 20Gy in five fractions and SIB to 30Gy in five fractions
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 27224066

Group type: EXPERIMENTAL
Intervention: Acuvue® Oasys® for Presbyopia (AOP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Air Optix® Aqua Multifocal (AOMF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Air Optix® Aqua Single Vision (AOSV)
Number of subjects: 42
Study: 24060806

Group type: EXPERIMENTAL
Intervention: Educational intervention (2-hour faculty lecture on cultural competence and student group presentation)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 146
Study: 22917599

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention consisting of manual tooth/gum brushing, 0.12% chlorhexidine oral rinse administered twice daily by nurses, and upright feeding positioning at meals.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned in the abstract.
Number of subjects: 0
Study: 19955007

Group type: EXPERIMENTAL
Intervention: Ideal self attributes
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ought self attributes
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Feared self attributes
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Disability
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 80
Study: 18158427

Group type: EXPERIMENTAL
Intervention: NESS L300 neuroprosthesis
Number of subjects: 24
Study: 17066294

Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic advisory intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 300
Study: 12828058

Group type: EXPERIMENTAL
Intervention: Monopolar cutter (thermal device)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Harmonic scalpel (non-thermal device)
Number of subjects: 20
Study: 10714046

Group type: EXPERIMENTAL
Intervention: Imipramine plus CBT
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo plus CBT
Number of subjects: 63
Study: 8885912

Group type: EXPERIMENTAL
Intervention: Oral methotrexate, 2.5 mg/day for 5 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1417466

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 3927339

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 10 mg amphetamine sulfate
Number of subjects: 13
Study: 31326043

Group type: EXPERIMENTAL
Intervention: Bass Intrasulcular Technique (BIT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (NI) with no brushing technique instructions
Number of subjects: 48
Study: 29467335

Group type: EXPERIMENTAL
Intervention: HDL containing apoE but not apoCIII
Number of subjects: 1967

Group type: COMPARATOR
Intervention: HDL containing apoCIII
Number of subjects: 1967
Study: 27153927

Group type: EXPERIMENTAL
Intervention: Hematocrit normalization (Hct 42%)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Exercise training (at Hct 30% and Hct 42%)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of Hct normalization and exercise training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Untrained phase at Hct 30%
Number of subjects: 27

Group type: COMPARATOR
Intervention: Untrained phase at Hct 42%
Number of subjects: 27
Study: 24758417

Group type: EXPERIMENTAL
Intervention: KRG root (3 g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: KRG ginsenosides extract
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: KRG polysaccharides extract
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cornstarch control
Number of subjects: 16
Study: 22428474

Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation (RBL)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined Hemorrhoidal Radiocoagulation (CHR)
Number of subjects: 75
Study: 20626209

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (1 g twice daily)
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Ciclosporin (2.5-4 mg/kg/day)
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 1262
Study: 18494959

Group type: EXPERIMENTAL
Intervention: Larval therapy ('bagged' and 'loose')
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard therapy (hydrogel)
Number of subjects: 35
Study: 16437318

Group type: EXPERIMENTAL
Intervention: Regular physical exercise (supervised aerobic exercise program for four months)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (15 age- and sex-matched healthy persons who did not exercise regularly)
Number of subjects: 11
Study: 12913770

Group type: EXPERIMENTAL
Intervention: S. sonnei-CRM(9)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: S. flexneri 2a-rEPA(succ)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 80
Study: 10384400

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7796089

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 50 mg/kg intravenous infusion in saline
Number of subjects: 18

Group type: COMPARATOR
Intervention: Quinine plus intravenous saline (Control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) and Control
Number of subjects: 18
Study: 2109477

Group type: EXPERIMENTAL
Intervention: Methohexital (100 mg induction, 10 mg.min‐1 maintenance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam (15 mg induction, 0.1 mg.min‐1 maintenance) + Flumazenil (0.53 mg mean dose)
Number of subjects: 0
Study: 7356888

Group type: EXPERIMENTAL
Intervention: Phenelzine treatment for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (5 patients after treatment only)
Number of subjects: 20
Study: 31575509

Group type: EXPERIMENTAL
Intervention: Pamrevlumab 30 mg/kg every 3 weeks for 48 weeks (16 infusions)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Number of subjects: 103
Study: 31201796

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 28
Study: 27906757

Group type: EXPERIMENTAL
Intervention: Immersive preoperative VR experience
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard preoperative experience
Number of subjects: 127
Study: 26343698

Group type: EXPERIMENTAL
Intervention: PUFA supplementation (1.3 g of PUFA and 10 mg of vitamin E daily for 12 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (11 mg of vitamin E daily for 12 weeks)
Number of subjects: 53
Study: 23068021

Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 149
Study: 21484037

Group type: EXPERIMENTAL
Intervention: Resistance exercise (6 exercises, 3 sets of 12, 10 and 8 reps, perceived exertion 11 to 13 on the Borg scale)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control session (resting on exercise machines)
Number of subjects: 8
Study: 19466963

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) and Pentoxifylline (PTX)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 16340949

Group type: EXPERIMENTAL
Intervention: Oligofructose (OFS) 8 g twice daily (16 g/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (dextrine maltose (DM)) 8 g twice daily (16 g/day)
Number of subjects: 10
Study: 15545348

Group type: EXPERIMENTAL
Intervention: Ad libitum meal composition
Number of subjects: 0

Group type: COMPARATOR
Intervention: National Cholesterol Education Program Step I diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: National Cholesterol Education Program Step II diet
Number of subjects: 0
Study: 11006176

Group type: EXPERIMENTAL
Intervention: Cyclical sequential norethisterone (NET)-based HRT with continuous 2 mg oral oestradiol valerate for three cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimegestone-based HRT regimens (0.05, 0.1, 0.25 and 0.5 mg/day from day 15-28 for six treatment cycles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural cycle (control samples)
Number of subjects: 0
Study: 9248777

Group type: EXPERIMENTAL
Intervention: 15 mg of mirtazapine in the fasting state
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 15 mg of mirtazapine after a high-fat meal
Number of subjects: 19
Study: 7714224

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2707980

Group type: EXPERIMENTAL
Intervention: Primary nursing
Number of subjects: 90

Group type: COMPARATOR
Intervention: Team nursing
Number of subjects: 90
Study: 740581

Group type: EXPERIMENTAL
Intervention: Progestogen (ethynodiol diacetate 9 microgram/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oestrogen (mestranol 0.9 microgram/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined therapy with oestrogen and progestogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progestogen in preliminary human study
Number of subjects: 0
Study: 31965830

Group type: EXPERIMENTAL
Intervention: Minimal anxiety at baseline
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: High pain self‐efficacy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Fear of movement
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Life satisfaction
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Low number of comorbidities
Number of subjects: 108
Study: 31709560

Group type: EXPERIMENTAL
Intervention: Single-case intervention randomization procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Excel-based software package for randomization
Number of subjects: 0
Study: 28724186

Group type: EXPERIMENTAL
Intervention: 4% topical formulation of InsP6 applied once a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hyaluronic acid gel (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4% topical formulation of InsP6
Number of subjects: 20
Study: 26237326

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Standard Methadone Care (Control)
Number of subjects: 323
Study: 24634205

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg every 2 weeks
Number of subjects: 67
Study: 23098097

Group type: EXPERIMENTAL
Intervention: Haemorrhoidal artery ligation (HAL)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Rubber band ligation (RBL)
Number of subjects: 350
Study: 19264143

Group type: EXPERIMENTAL
Intervention: Invasive EEG recordings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-invasive EEG recordings
Number of subjects: 0
Study: 17888460

Group type: EXPERIMENTAL
Intervention: GABA‐A/benzodiazepine receptor inverse agonist selective for the alpha5 subtype (a5IA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol (mean breath concentration 150mg/100ml)
Number of subjects: 0
Study: 15073706

Group type: EXPERIMENTAL
Intervention: Cross-clamp applied only to the aorta (Group 1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cross-clamp applied to both the aorta and pulmonary artery (Group 2)
Number of subjects: 22
Study: 11234776

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.3 mg, i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycopyrrolate (0.2 mg, i.v.)
Number of subjects: 0
Study: 9587372

Group type: EXPERIMENTAL
Intervention: Post-operative pelvic external irradiation
Number of subjects: 0
Study: 8385525

Group type: EXPERIMENTAL
Intervention: Lisinopril 10mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril 10mg once daily
Number of subjects: 0
Study: 3097109

Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Astemizole (in open trial)
Number of subjects: 51
Study: 29505689

Group type: EXPERIMENTAL
Intervention: TENS treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TENS placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 26867697

Group type: EXPERIMENTAL
Intervention: Mindfulness-based diet and exercise intervention
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (diet and exercise intervention without mindfulness)
Number of subjects: 194
Study: 25231730

Group type: EXPERIMENTAL
Intervention: High-Ca group (actual Ca intake: 1243 mg/d)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Medium-Ca group (actual Ca intake: 985 mg/d)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Ca supplementation
Number of subjects: 220
Study: 22664798

Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg QD
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Edoxaban 45 mg QD
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg QD
Number of subjects: 536

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 536
Study: 19520690

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab plus PDT using a light dose of 25 J/cm2 (group 1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab plus PDT using a light dose of 12 J/cm2 (group 2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab plus sham PDT (group 3)
Number of subjects: 36
Study: 17671809

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 177
Study: 14963719

Group type: EXPERIMENTAL
Intervention: Betamethasone solution (0.4 mg/ml)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 25
Study: 11888583

Group type: EXPERIMENTAL
Intervention: Zidovudine and lamivudine
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Zidovudine and abacavir
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Lamivudine and abacavir
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 10207641

Group type: EXPERIMENTAL
Intervention: Education plus counseling (E + C)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Standard education model
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Both interventions (E + C and Standard education)
Number of subjects: 298
Study: 8652254

Group type: EXPERIMENTAL
Intervention: Audiotape of a previous consultation (n = 63)
Number of subjects: 117

Group type: COMPARATOR
Intervention: No audiotape (Control group, n = 54)
Number of subjects: 117
Study: 2073774

Group type: EXPERIMENTAL
Intervention: General practitioner-written invitations to attend screening mammography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General practitioner-written invitations with an appointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General practitioner-written invitations without an appointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reminder letters sent to nonrespondents who had attended the practice in the previous 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no reminder letter)
Number of subjects: 0
Study: 7271298

Group type: EXPERIMENTAL
Intervention: Chemotherapy (2-year course)
Number of subjects: 252

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 252
Study: 31857198

Group type: EXPERIMENTAL
Intervention: High-intensity cycling for 17 min
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling for 17 min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Minimal-intensity cycling for 17 min
Number of subjects: 50
Study: 31512682

Group type: EXPERIMENTAL
Intervention: Non-working students
Number of subjects: 298

Group type: COMPARATOR
Intervention: Working students
Number of subjects: 298
Study: 28294697

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1064 nm)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 46
Study: 26459273

Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen with glargine once daily and glulisine before meals
Number of subjects: 72

Group type: COMPARATOR
Intervention: Premixed human insulin (30% regular insulin and 70% NPH insulin) twice daily
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen
Number of subjects: 72

Group type: COMPARATOR
Intervention: Premixed human insulin
Number of subjects: 72
Study: 23465334

Group type: EXPERIMENTAL
Intervention: High parental investment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low parental investment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-risk children
Number of subjects: 0
Study: 21795430

Group type: EXPERIMENTAL
Intervention: Calcium doses ≥1000 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Calcium dose of 800 mg
Number of subjects: 54
Study: 19252156

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811
Study: 17846069

Group type: EXPERIMENTAL
Intervention: Incremental speed-dependent treadmill training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study: 15506570

Group type: EXPERIMENTAL
Intervention: Single question screening approach
Number of subjects: 2800

Group type: COMPARATOR
Intervention: CAGE screening approach
Number of subjects: 2800
Study: 11723348

Group type: EXPERIMENTAL
Intervention: E-mail/web-based survey
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional postal mail survey
Number of subjects: 114
Study: 9552949

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 868

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 868
Study: 7917911

Group type: EXPERIMENTAL
Intervention: Interferon α(2b) (IFN‐α(2b))
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal donors
Number of subjects: 29
Study: 2498565

Group type: EXPERIMENTAL
Intervention: Continuous regimen of propranolol (4 or 3 times daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intermittent regimen of propranolol (twice daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propranolol used for 12 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Twice-daily regimen of propranolol
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Higher daily doses of propranolol
Number of subjects: 48
Study: 31216205

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27930613

Group type: EXPERIMENTAL
Intervention: Community empowerment-based combination HIV prevention model (Project Shikamana)
Number of subjects: 496
Study: 26231305

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg administered monthly
Number of subjects: 500

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab 0.5 mg administered as needed (PRN) after 3 monthly loading doses
Number of subjects: 500